Hualan Biological Engineering (002007) Fundamentals 2026 — P/E 27.7x, Revenue Analysis | SniperIQ
Hualan Biological Engineering (002007) is a CN-listed Healthcare company in Biotechnology with a market capitalization of ¥24.1B, trading at ¥13.19 on the SHZ. This SniperIQ fundamentals page covers Hualan Biological Engineering's valuation (P/E 27.7x, P/B 2.1x), profitability (net margin 19.1%), revenue (¥4.6B in FY2025), balance-sheet quality, and AI signal context — from live market data, research only.
Full research coverage
- 8-Quarter Revenue & Margin Trend
- Debt Maturity & Coverage
- Peer Valuation Comparison
- Free Cash Flow & Owner Earnings
- AI Signal + Institutional Flow
- DCF Valuation Model
Frequently Asked Questions
What is Hualan Biological Engineering's market cap?
Hualan Biological Engineering (002007) has a market capitalization of approximately ¥24.1B, trading at ¥13.19 on the SHZ. Market cap moves with the live share price.
What is Hualan Biological Engineering's P/E ratio?
Hualan Biological Engineering's trailing twelve-month P/E ratio is 27.7x, with a price-to-book (P/B) of 2.1x. Valuation multiples are best compared with Healthcare sector peers rather than read in isolation.
How profitable is Hualan Biological Engineering?
Hualan Biological Engineering runs a net profit margin of 19.1%, a gross margin of 56.1%, and an operating margin of 23.4%. Margins and ROE indicate how efficiently the business converts sales into profit and shareholder returns.
How much revenue does Hualan Biological Engineering generate?
Hualan Biological Engineering reported revenue of ¥4.6B for fiscal year 2025, with net income of ¥940M and earnings per share (EPS) of 0.52. SniperIQ tracks the full 8-quarter revenue and margin trend on the research dashboard.
Does Hualan Biological Engineering pay a dividend?
Hualan Biological Engineering offers a trailing dividend yield of about 7.6%. Dividend sustainability depends on payout ratio, free cash flow, and earnings stability — all tracked in SniperIQ's fundamentals view.
Is Hualan Biological Engineering financially healthy?
Hualan Biological Engineering carries a debt-to-equity ratio of 0.00x and a current ratio of 6.57x, with a market beta of 0.36. Lower leverage and a current ratio above 1.0 generally signal a stronger balance sheet.
Is Hualan Biological Engineering a good stock to buy in 2026?
SniperIQ provides research-only market intelligence, not personalised financial advice or a buy/sell call. For Hualan Biological Engineering (002007) the key facts are: market cap ¥24.1B, P/E 27.7x, revenue ¥4.6B, 52-week range 11.72-18.39. Weigh valuation, profitability, growth, and balance-sheet strength against Healthcare peers and form your own view.
Track Hualan Biological Engineering's full fundamentals live
Get Hualan Biological Engineering's 8-quarter revenue and margin trend, peer comparison, DCF model, and AI signal on the SniperIQ research dashboard.